European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading

MT Newswires Live03-30 23:07

European equities traded in the US as American depositary kicked off the week higher late Monday morning, rising 0.78% to 1,700.55 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by petroleum refiner Equinor (EQNR) and internet advertising firm Criteo (CRTO), which rose 3.8% and 3.4%, respectively. They were followed by software firm SAP (SAP) and pharmaceutical company Novo Nordisk (NVO), which were up 1.4% each.

The decliners from continental Europe were led by medical device maker EDAP TMS (EDAP) and biopharmaceutical company Cellectis (CLLS), which dropped 2.8% and 2.5%, respectively. They were followed by accommodations booking company trivago (TRVG) and biotech firm BioNTech (BNTX), which lost 1.8% and 0.4%, respectively.

The gainers from the UK were led by pharmaceutical company AstraZeneca (AZN), which advanced by 2.9%. It was followed by pharmaceutical company Silence Therapeutics (SLN) and utilities company National Grid (NGG), which increased 2.4% and 2.3%, respectively.

The decliners from the UK and Ireland were led by biopharmaceutical companies Mereo BioPharma Group (MREO) and Amarin (AMRN), fell 2.9% and 1%, respectively. They were followed by communications company WPP (WPP) and hospitality company InterContinental Hotels Group (IHG), which were down 0.9% and 0.5%, respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment